Integration of buprenorphine into primary HIV care
Report from the Forum for Collaborative HIV Research
Opioid dependence and HIV both represent serious public health threats to the US. The Drug Addiction Treatment Act of 2000 allowing prescription of Schedule III-V drug dependence treatment medications in office-based practices, and the approval of buprenorphine and buprenorphine/naloxone provide promising new directions for the treatment of opioid addiction and particularly, for improved care of patients with HIV-infection and opioid dependence. However, the integration of buprenorphine into HIV primary care has not been as rapid or extensive as expected.
The Forum for Collaborative HIV Research convened experts in HIV medicine and/or opioid dependence treatment from academia, community and private practices, patient community, US government agencies and industry to review issues associated with the integration of buprenorphine into HIV primary care, identify barriers to this integration and develop recommendations for increased uptake of this new opioid treatment modality into HIV primary care settings.
The report may be downloaded as a PDF file [736k] from:
For workshop presentations, please see:
Buprenorphine in the Primary HIV Care Setting
For hard-copy requests, please contact: firstname.lastname@example.org
The Forum for Collaborative HIV Research